Viridian Therapeutics (VRDN)

• Market cap: $2.96B
• 1 day: -1.65%
• 5 days: -4.7%
• 1 month: -1.37%
• 3 months: 43.74%
• 6 months: 121.89%
• Year to date: 56.98%
• 1 year: 58.75%
• 5 years: 84.64%
• 10 years: -81.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Employees: 143